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Abstract
Background: Complementary and alternative medicine (CAM) use is common among cancer patients.
This paper reviews the use of CAM in a series of patients with locally advanced breast cancer (LABC).
Methods: Women with LABC attending a specialist clinic at a single Canadian cancer centre were
identified and approached. Participants completed a self-administered survey regarding CAM usage, beliefs
associated with CAM usage, views of their risks of developing recurrent cancer and of dying of breast
cancer. Responses were scored and compared between CAM users and non-users.
Results: Thirty-six patients were approached, 32 completed the questionnaire (response rate 89%).
Forty-seven percent of LABC patients were identified as CAM users. CAM users were more likely to be
younger, married, in a higher socioeconomic class and of Asian ethnicity than non-users. CAM users were
likely to use multiple modalities simultaneously (median 4) with vitamins being the most popular (60%).
Motivation for CAM therapy was described as, "assisting their body to heal" (75%), to 'boost the immune
system' (56%) and to "give a feeling of control with respect to their treatment" (56%). CAM therapy was
used concurrently with conventional treatment in 88% of cases, however, 12% of patients felt that CAM
could replace their conventional therapy. Psychological evaluation suggests CAM users perceived their risk
of dying of breast cancer was similar to that of the non-Cam group (33% vs. 35%), however the CAM group
had less severe anxiety and depression.
Conclusion: The motivation, objectives and benefits of CAM therapy in a selected population of women
with LABC are similar to those reported for women diagnosed with early stage breast cancer. CAM users
display less anxiety and depression and are less likely to believe they will die of their breast cancer.
However the actual benefit to overall and disease free survival has yet to be demonstrated, as well as the
possible interactions with conventional therapy. Consequently more research is needed in this ever-
growing field.
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Background
Cancer patients take a wide range of complementary and
alternative medicines (CAM). These include ingested ther-
apies such as herbs, and vitamins, homeopathic remedies
and traditional Chinese medicines as well as psychologi-
cal, physical and spiritual techniques [1-4]. Currently
between 20% and 84% of cancer patients are using CAM
therapies [1-6]. Predisposing characteristics for CAM use
have been shown to include a high level of education,
high-income bracket, ethnicity, marital status, adjuvant
therapy and presence of anxiety or depression [1-3,7-9].
While no data reports improved survival or disease free
interval with the use of CAM [10], many cancer patients
attribute CAM therapy with providing them a feeling of
control over their disease. CAM therapies are also believed
to have properties such as, 'boosting' the immune system
and preventing/treating cancer [2,11]. Studies comparing
CAM use in women with advanced stage cancer to those
with early stage cancer find goals of therapy to be similar,
therapeutic and psychological [11]: i.e. to relieve symp-
toms [2,5,9,11], to exude greater control over their life
and express hopefulness over there disease and life [7].
Patients with locally advanced breast cancer (LABC) are a
unique population. They have tumours that are frequently
large, involve the regional lymph nodes or extend beyond
the breast tissue [12]. Even with aggressive therapy the 5-
year survival rate for these patients is poor at around 55%
[13].
We recently reported in a population of women with
breast cancer including all stages of disease, that CAM
users are more likely to be younger, better educated and in
full time employment compared to non-users [14]. In
addition while there was no difference between CAM
usage with respect to tumour stage, CAM therapy was
associated with an increased perception of breast cancer
recurrence and of breast cancer-related death [14].
The objective of this study was to identify the overall
usage of CAM in patients with LABC, determine their
motivation and objectives for usage. Secondarily the effect
of CAM therapy on patient's beliefs and perceptions of
their disease was examined.
Methods
The breast cancer site at the Toronto-Sunnybrook
Regional Cancer Centre (TSRCC) has Canada's only spe-
cialist multidisciplinary clinic for women with LABC.
Between June 2003 and June 2004 consecutive outpa-
tients with a diagnosis of breast cancer were screened for
eligibility. Only patients with locally advanced breast can-
cer were included in this study. Patients were invited to
participate in this study examining the prevalence of CAM
therapy by a study nurse prior to their visit with their
oncologist. All surveys were completed under the supervi-
sion of a trained data manager in a private room, and any
questions or concerns were addressed by their own oncol-
ogist (ER or MC). Patients were reassured that participa-
tion in this study in no way altered there medical care.
Patients were excluded if they did not have English profi-
ciency or did not give informed consent. Independent
confirmation of diagnosis, stage and treatment in all
patients was performed by one of the investigators (ER or
MC). Study approval was obtained from the local
Research and Ethics Board.
The self-administered questionnaire (appendix 1) was
developed to obtain information on demographics, con-
ventional therapy and CAM use [14]. Sixteen of the most
common reasons for using CAM and patient perceptions
of CAM therapy were derived from the current literature
and listed as choices [2]. Patient's beliefs and perceptions
of their disease were assed using a Likert scale with larger
scores representing higher perceptions of risk [14]. Beliefs
were scored on a scale ranging from 1(strongly disagree)
to 5 (strongly agree), while perceptions were scored on a
scale from very unlikely (-2) to highly likely (+2).
The Hospital Anxiety and Depression scale was used to
assess psychological distress [15]. This instrument gives
separate measures of anxiety and depression with seven
items for anxiety and seven items for depression (range of
scores from 0 to 21). Each item (anxiety and depression)
is scored separately. Scores <7 represent a non-case, scores
8–10 represent a possible case and those above 10 repre-
sent significant disease related to anxiety or depression.
The sensitivity of this test has been reported to be 74%
with a specificity of 75% [16].
Due to the small number of patients the results of this
study are presented descriptively as means, medians and
proportions. Statistical examination was unable to show
significant difference between the CAM users and Non
CAM users due to small sample size and inadequate statis-
tical power. Use of comparative tests would have
increased the probability of a type I error.
Results
Demographics
Thirty-two of the 36 patients approached completed the
questionnaire (response rate of 89%). Patient demo-
graphics are outlined in Table 1. All patients were female,
mean age of 54 (range 29–91 years). Fifteen of the 32
patients (47%) were identified as CAM users. The CAM
users tended to be younger (mean 49 years vs. 59 years)
and 86% were in a current relationship versus 52% of
non-Cam users. Over 80% of both groups had completed
high school, while 30% in the non-CAM users had a grad-BMC Cancer 2006, 6:39 http://www.biomedcentral.com/1471-2407/6/39
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uate degree compared with 13% in the CAM group. The
numbers of patients remaining at work, on sick leave, or
at home were comparable as was income distribution
between groups. The diverse ethnic population reflects
our patient population.
Conventional therapy
The CAM user group was more likely to have had more
intensive therapy for breast cancer, 30% of patients in the
CAM group had all three modalities of treatment; surgery,
chemotherapy and radiation in comparison with 14% in
Table 1: Demographics of the LABC population
All LABC Patients n = 32 CAM Patients n = 15 Non-CAM Patients n = 17
Mean Age (years) 54 49 59
Range 29 to 91 29 to 73 34 to 91
Ethnic Background
African-Canadian 9% 0% 17%
Asian 9% 13% 5%
Caucasian 46% 40% 52%
Jewish 9% 20% 0%
Middle Eastern 3% 6% 0%
Mixed Ethnicity 3% 0% 5%
Unknown 6% 13% 0%
Marital Status
Married/Common Law 68% 86% 52%
Widowed/Divorced 12% 0% 23%
Single 18% 13% 23%
Education:
Did not completed 12% 13% 11%
Completed high school 34% 33% 35%
Completed university/college 31% 40% 23%
Completed Post Graduate Degree 21% 13% 29%
Employment Status
Full time 28% 26% 29%
Part time 6% 13% 0%
Unemployed/homemaker 31% 20% 41%
Sick Leave 34% 40% 29%
Household Income (10,000 
CND)
0–30 25% 33% 18%
31–70 41% 33% 50%
71–100 9% 13% 6%
>100 22% 20% 25%
Breast Cancer Therapies
Surgery 40% 46% 35%
Chemotherapy 81% 93% 70%
Radiation Therapy 25% 33% 17%
Hormonal Therapy 37% 40% 35%BMC Cancer 2006, 6:39 http://www.biomedcentral.com/1471-2407/6/39
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the non CAM user group (Table 1). The use of hormonal
therapy was equal between the groups. The presence of
private insurance and a family physician was also more
common in those using CAM techniques (66% vs. 58%)
and (100% vs. 88%) respectively. CAM users were also
more likely to be involved in cancer support groups (20%
vs. 5%) and if not, more interested in joining one than
their counter parts (25% vs. 13%).
Complementary medicine
The use of complementary alternative medicine was
divided into dietary, herbal-homeopathy, psychological
and physical methods (Table 2). Many patients used more
than one modality with a mean of 4, (range 1–11). Forty
percent of the CAM group had used these techniques prior
to their diagnosis of breast cancer and all continued
throughout therapy. The most common source of infor-
mation about complementary medicine was a conven-
tional physician (40%) followed by pharmacist and
friend (20%). Two thirds of patients (10) researched CAM
therapy prior to starting, 5 patients paid for consultation
with prices ranging from $60 to $200 CDN. The cost of
CAM varied between patients with the majority spending
up to $50 CDN/month (46%) some however spending
over $100 CDN/month (23%).
The most common form of CAM was vitamin therapy,
and over 60% of CAM users had taken supplements and
additives. Forty percent of the patients using CAM were on
restrictive diets; either low in fat, vegetarian or using soy
products. Two thirds of patients used psychological tech-
niques including faith and spiritual healing (40%) and
guided imagery (26%). 86% of patients felt their CAM
was helpful and beneficial for their disease. Sixty four per-
cent of patients using CAM had informed their oncologist
and believed it was important information for their oncol-
ogist to know.
Beliefs associated with CAM
Patients' reasons and beliefs regarding CAM therapy were
explored asking questions phrased, "Do you believed
CAM......?"(Table 3). The most common reason for CAM
use in this population was "to assist the body's natural
forces to heal"(75%). Other common reasons were: to
assist other treatments (62%), relieve symptoms (62%),
and increase quality of life (62%). 56% felt there would
Table 2: CAM use among LABC patients (n = 15)
Mode of CAM Use: % Population (n = 15)
Dietary
Macrobiotic 13
Vitamin therapy 66
Megavitamins 20
Minerals 40
Low-fat or vegetarian diets 40
Soy Products 26
Herbal/Homeopathy 20
Psychological Methods
Meditation 10
Guided Imagery 26
Hypnosis 6
Faith and Spiritual 40
Physical Methods
Massage therapy 26
Acupuncture 6
Acupressure 6
Yoga 26
Tai Chi 13
Alternative Providers:
Chiropractor 6
Naturopathic Doctor 6
Acupuncturist 6
TCM Doctor 6
Others 13BMC Cancer 2006, 6:39 http://www.biomedcentral.com/1471-2407/6/39
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not be any side effects and 43% believed that CAM was
perfectly safe with no adverse effects or interactions with
other cancer therapies. 12.5% of patients felt that CAM
therapy would make them less likely to accept conven-
tional treatments and 18% believed it would reduce the
chance that other therapies would work. Two patients
refused conventional treatment, believing the CAM ther-
apy would cure their breast cancer. One quarter of patients
believed CAM therapy would prevent the spread of their
disease and 18% believed it would cure the cancer. Half of
respondents were indifferent with respect to the belief that
CAM therapy would cure their cancer, prevent its spread
and/or prevent a recurrence.
Perceived risk of breast cancer and associated anxiety and 
depression
The risk assessment asked four questions to show patients'
perception of developing and dying of recurrent breast
cancer. CAM users believed they would more likely die of
something other than their breast cancer (72% vs 42%)
and their cancer was less likely to recur elsewhere after
treatment (53% vs 35%). However over 60% of all
patients with LABC (CAM users and non-users) felt there
disease would not recur in the treated breast or cause their
death (Table 4).
The Hospital Anxiety and Depression Scale (HADS) [15]
(figure 1) was included to demonstrate the psychological
health of the patient population. Anxiety was seen in both
groups CAM user and non-CAM user. Those patients
Table 3: Beliefs and perceptions of CAM therapy (n = 15).
Beliefs Percentages
I believe CAM therapy will Unlikely (1,2) Indifferent (3) Likely (4,5)
Cure Cancer 31.3% 50.0% 18.8%
Prevent Spread 25.0% 50.0% 25.0%
Assist other treatments 25.0% 12.5% 62.5%
Relieve symptoms 18.8% 18.8% 62.5%
Have side effects 56.3% 12.5% 31.3%
Weaken body's natural reserves 62.5% 18.8% 18.8%
Patient's Fault if they don't work 75.0% 18.8% 6.3%
Assist the body's natural forces to 
heal
6.3% 18.8% 75.0%
Easy to understand how they work 37.5% 25.0% 37.5%
Boost to Immune System 18.8% 25.0% 56.3%
Perfectly safe 25.0% 31.3% 43.8%
Increase Quality of Life 6.3% 31.3% 62.5%
Feeling of control over the cancer 25.0% 18.8% 56.3%
Prevent recurrence of Cancer 18.8% 56.3% 25.0%
Reduce the chance that other 
therapies will work
37.5% 43.8% 18.8%
Makes them less likely to accept 
conventional treatments
50.0% 37.5% 12.5%
Table 4: Risk perception in LABC patients
Risk Perception
How likely is it that....?
Non CAM Users  % people who rated (n = 17) CAM Users  % people who rated (n = 15)
Cancer recurrence in same breast
Unlikely 53 (9) 57 (8)
Likely 47 (8) 43 (7)
Cancer recurrence elsewhere
Unlikely 35 (6) 53 (8)
Likely 65 (11) 47 (7)
Likely die of cancer
Unlikely 65 (11) 67 (10)
Likely 35(6) 33.(5)
Likely die of something else
Unlikely 58 (10) 27 (4)
Likely 42 (7) 73 (11)BMC Cancer 2006, 6:39 http://www.biomedcentral.com/1471-2407/6/39
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using CAM therapy has less severe anxiety. The highest
anxiety scores in the CAM group were recorded in patients
using greater than four modalities of CAM. CAM users'
described their depression as mild more frequently in
comparison to the non-CAM users.
Discussion
Depending on the population studied, the prevalence of
CAM use among breast cancer patients is 20%–84% [1-6].
Forty seven percent of patients with LABC at our institu-
tion were CAM users, similar to the proportion of users in
a non-stage specific group at our institution [14]. Variance
in degree of use has been attributed to socio-demographic
and clinical differences in study populations more so than
stage of disease.
Women with LABC are a unique population. They present
to medical attention with breast cancer at an advanced
stage and they therefore have a poorer prognosis [17].
Reasons proposed for presentation with advanced disease
depends largely on the population studied and may
include the biology of the tumour, unwillingness of the
patient to consult medical attention due to fear, denial
[18] or pursuit of alternative therapy [19-21], or lack of
patient education [22] but is largely unknown. Most
patients, as in our study, use CAM therapy as an adjunct
to conventional treatment [2,5]. Only 12% of our patients
refused conventional treatment preferring CAM alterna-
tives. Despite widespread use of CAM therapy among can-
cer patients, the efficacy in the course of cancer therapy
has not been substantially confirmed [10,18]. Jacobson et
al. reviewed English language publications from 1980 to
1997, looking for supportive evidence for CAM therapy
and although most studies lacked vigorous scientific
design, there was no definite survival benefit with the
addition of CAM therapy [10]. Physical methods such as
acupuncture, massage and mind-body techniques have
modest evidence to show patient benefit with respect to
anxiety, depression and quality of life [23,24]. The use of
CAM therapies has also been shown to correlate with
patients coping styles and may fulfil an important psycho-
logical need in some patients [25].
The reasons patients give for using CAM are varied, but
many concentrate around feelings of control over therapy
or of aiding the body over come disease and harmful
effects of traditional therapy [4,26,27]. Most CAM tech-
niques and substances are felt to be innocuous, as most
patients associate 'natural' therapy with safe and non-
toxic therapy, a view supported by many health food
stores [19]. Side effects and adverse effects are conse-
quently minimized and as a result, poorly communicated
to consumers. This perception of 'natural' may encourage
patients to take CAM to the exclusion of the conventional
therapies with the multiple documented side effects and
adverse events [19]. Indeed the global consumption of
these therapies continues to rise [9].
Our patient population using CAM was similar to others
reported; all woman, in a higher income bracket, currently
in a relationship, and more likely to join or be part of a
support group [2,14,25,28,29]. However, the non-CAM
users in our study were more likely to have graduate
degrees and thus higher education. This inverse relation-
ship between CAM use and education has been previously
described by Dy et al. where participants in phase I trials
were found to be less likely to take pharmacologic CAM if
they had attained a high level of formal education[30].
However, the majority of evidence supports a higher use
of CAM therapy in those with higher socioeconomic and
education levels [2,5,9,25,28,29]. Ethnicity has also been
found to be a CAM stratifying characteristic [26,29].
Although we have a small sample size, those of Asian her-
itage were more likely to pursue CAM therapy. This may
Anxiety and Depression Distribution Among Patients with  LABC Figure 1
Anxiety and Depression Distribution Among Patients with 
LABC.BMC Cancer 2006, 6:39 http://www.biomedcentral.com/1471-2407/6/39
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emphasize the importance of community and societal
support on patient treatment decisions and ultimately
cultural acceptance of traditional medicine.
CAM users in our study were more likely to have the sup-
port of a partner, family doctor, and be in or interested in
joining a support group. This difference in amount of sup-
port whether from a partner, family doctor or group delin-
eates our population in a dramatic fashion. The
participation in a support group is recognized as highly
predictive of CAM use, why is not known but maybe
intrinsic to the patients joining the group or as an end
result of group interaction [2,21,29,31].
Thirty percent of our patients in the CAM group compared
with 14% in the non-CAM group had combination treat-
ment with surgery, chemotherapy and radiation. Simi-
larly, the literature reflects, the more strenuous the
treatment the more likely patients are to use CAM [5,17].
Most women used CAM as an adjunct to this intensive
therapy, 75% believe that it helped with symptom con-
trol, assisted traditional treatments, boosts the immune
system and increased the quality of life, while attributing
it little to no curative properties. The majority (86%) of
our patients taking CAM believed that it helped and were
positive about their experience. However, two women in
our study refused mainstream treatment and were persist-
ing with primary CAM therapy. Due to the questionnaire
form we were unable to better characterize this segment of
our population.
Earlier studies showed patients using CAM had higher lev-
els of stress, exhibited more severe anxiety and worse
depression[3]. These patients consequently had a worse
quality of life. As we have previously published, the CAM
users in an unselected population of breast cancer patients
exhibited higher levels of anxiety and depression over the
non-users[14]. However, our LABC patients, in actuality
seemed to be suffering less severe anxiety and felt their
mood to be higher (Figure 1). This maybe explained by
Moshen et al., who postulated there are two subgroups of
patients, one group who actively copes with stress and
another who has considerable adjustment problems [25].
The latter group with adjustment problems were more
likely to use greater than four CAM therapies and express
a depressive coping behaviour. The five patients who used
greater than four CAM therapies in our study described a
greater level of anxiety but not depression.
Anxiety is a feeling centred on fear and involves worry,
apprehension and dread. Those patients with strong
beliefs in CAM therapy are able to lessen these feelings,
while those who are 'non-believers' are unable assuage
this anxiety. Depression meanwhile, is associated with
feelings of sadness and hopelessness; CAM therapy pro-
vides a positive influence on conventional treatment and
may moderate these thoughts. Differences between CAM
users and nonusers with respect to anxiety and depression
maybe difficult to show in patients with advanced cancers
i.e. LABC, and may explain the difference between the
non selected and LABC population.
Our studies primary limitation is sample size, and
although our breast centre specializes in treatment of
locally advanced breast cancer; with increased screening
and education this is becoming a rare diagnosis. Conse-
quently statistical evaluation of the data was unable to be
performed and instead a descriptive study was chosen.
Small sample size may also account for the discrepancy
seen in non-CAM users having a higher level of education.
Patient selection in an oncology clinic may have over-
looked patients avoiding conventional medicine for treat-
ment of their breast cancer and selection bias may be
present. In conclusion, due to the fact this is a single insti-
tution study, where the diagnosis and treatment of LABC
is a priority the results may not be comparable to other
non-selected populations of breast cancer patients.
Conclusion
Studies are needed to determine the mechanism of action
of many of the popular additives, and thus elucidate the
side effects and adverse effects. Certainly, CAM therapies
are used in part as coping mechanisms by many patients.
However the benefits or drawback of this type of therapy
is poorly understood, consequently more education and
research aimed at both physician and patient is necessary
to elucidate the complex psychotherapeutic effect of many
of these techniques.
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